Pharma BD Deal Intelligence

Endo Health Solutions Inc. / Paladin Labs Inc.

2013 · Acquisition/Merger · $1.6B · Complete

Announcement Sentiment

Strongly positive

Endo to acquire Paladin Labs in stock-and-cash transaction valued ~$1.6B; folded both into new Irish holding company (tax inversion). $75M expected annual cost synergies.

Did it work? Outcome assessment

Strategic verdict

Partially Achieved

Financial impact

Neutral

Pipeline outcome

Mixed

Assessment window: 10yr post-close.

Key facts

Announced Nov 05, 2013
Closed Feb 28, 2014
Deal value $1.6B
Deal type Acquisition/Merger
Therapeutic area Specialty pharmaceuticals (Canada/EM)
Indications Specialty pharmaceuticals (Canada/EM)
Key assets Canadian specialty portfolio (Plan B, Trianal, Acquadeen, Triderm)
Mechanism Mixed branded specialty/OTC

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals